Please try another search
For the fiscal year ended 31 December 2020, FivePrime Therapeutics Inc revenues decreased 11% to $13.2M.Net loss decreased 39% to $84.3M. Revenues reflectCollaboration decrease of 45% to $8.2M. Lower net lossreflects Research and development - Balancing val decreaseof 38% to $65.8M (expense), Stock-based Compensation in SGAdecrease of 53% to $6.9M (expense), Stock-basedCompensation in R&D decrease of 59% to $3.3M (expense).
Period Ending: | Dec 31, 2020 | Sep 30, 2020 | Jun 30, 2020 | Mar 31, 2020 |
---|---|---|---|---|
Total Revenue | 13.18 | 2.05 | 3.42 | 8.41 |
Gross Profit | ||||
Operating Income | -92.87 | -33.11 | -17.14 | -20.63 |
Net Income | -84.33 | -26.42 | -16.94 | -20.12 |
Period Ending: | Dec 31, 2020 | Sep 30, 2020 | Jun 30, 2020 | Mar 31, 2020 |
---|---|---|---|---|
Total Assets | 331.65 | 160.38 | 185.34 | 202.97 |
Total Liabilities | 66.55 | 65.15 | 65.4 | 68.43 |
Total Equity | 265.1 | 95.23 | 119.94 | 134.54 |
Period Ending: | Dec 31, 2020 | Sep 30, 2020 | Jun 30, 2020 | Mar 31, 2020 |
---|---|---|---|---|
Period Length: | 12 Months | 9 Months | 6 Months | 3 Months |
Cash From Operating Activities | -64.65 | -51.39 | -36.06 | -15.07 |
Cash From Investing Activities | -110.63 | 32 | 39.05 | 27.24 |
Cash From Financing Activities | 188.91 | -0.39 | -0.08 | -0.28 |
Net Change in Cash | 13.62 | -19.78 | 2.91 | 11.89 |
Unlock access to over 1000 metrics with InvestingPro
View advanced insights on financial statements, including growth rates and metrics that provide an in-depth view of the company's historical and forecasted financial performance.
Are you sure you want to block %USER_NAME%?
By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.
%USER_NAME% was successfully added to your Block List
Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.
I feel that this comment is:
Thank You!
Your report has been sent to our moderators for review